<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PARP Inhibitors Cancer</title>
	<atom:link href="http://www.parpinhibitorscancer.com/feed" rel="self" type="application/rss+xml" />
	<link>http://www.parpinhibitorscancer.com</link>
	<description>Information on PARP Inhibitors and Cancer</description>
	<lastBuildDate>Mon, 02 Jan 2012 03:27:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3</generator>
		<item>
		<title>Olaparib Phase 3 Development Discontinued by AstraZeneca</title>
		<link>http://www.parpinhibitorscancer.com/parpinhibitornews/olaparibadvancedovariancancer.html</link>
		<comments>http://www.parpinhibitorscancer.com/parpinhibitornews/olaparibadvancedovariancancer.html#comments</comments>
		<pubDate>Mon, 02 Jan 2012 03:26:42 +0000</pubDate>
		<dc:creator>Parp Inhibitors</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[astrazeneca]]></category>
		<category><![CDATA[olaparib]]></category>
		<category><![CDATA[ovarian cancer]]></category>

		<guid isPermaLink="false">http://www.parpinhibitorscancer.com/?p=95</guid>
		<description><![CDATA[(January 1, 2012) In a surprise announcement, AstraZeneca put out a press release in late December announcing the cancellation Phase 3 development for olaparib. The official reason given for abandoning development was as follows: &#8220;The decision to discontinue olaparib’s development in serous ovarian cancer was made following a review of an interim analysis of a <a href='http://www.parpinhibitorscancer.com/parpinhibitornews/olaparibadvancedovariancancer.html'>[...]</a>]]></description>
		<wfw:commentRss>http://www.parpinhibitorscancer.com/parpinhibitornews/olaparibadvancedovariancancer.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Triple Negative Breast Cancer and PARP Inhibitors</title>
		<link>http://www.parpinhibitorscancer.com/videos/triplenegativebreastcancerparpinhibitors.html</link>
		<comments>http://www.parpinhibitorscancer.com/videos/triplenegativebreastcancerparpinhibitors.html#comments</comments>
		<pubDate>Sat, 04 Jun 2011 16:59:07 +0000</pubDate>
		<dc:creator>Parp Inhibitors</dc:creator>
				<category><![CDATA[Videos]]></category>

		<guid isPermaLink="false">http://www.parpinhibitorscancer.com/?p=91</guid>
		<description><![CDATA[In this video, Dr. Robert Carlson, MD, talks about triple negative breast cancer and PARP inhibitors. Dr. Carlson is a Professor of Medicine at at the Stanford Comprehensive Cancer Center. In part, he talks about the PARP pathway and how PARP inhibitors allow a different approach to DNA cell repair and cancer treatment. Here&#8217;s the <a href='http://www.parpinhibitorscancer.com/videos/triplenegativebreastcancerparpinhibitors.html'>[...]</a>]]></description>
		<wfw:commentRss>http://www.parpinhibitorscancer.com/videos/triplenegativebreastcancerparpinhibitors.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Clovis to Develop Pfizer&#8217;s PARP Inhibitor</title>
		<link>http://www.parpinhibitorscancer.com/parpinhibitornews/clovispfizerparpinhibitor.html</link>
		<comments>http://www.parpinhibitorscancer.com/parpinhibitornews/clovispfizerparpinhibitor.html#comments</comments>
		<pubDate>Sat, 04 Jun 2011 16:44:24 +0000</pubDate>
		<dc:creator>Parp Inhibitors</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.parpinhibitorscancer.com/?p=88</guid>
		<description><![CDATA[Clovis Oncology will develop Pfizer&#8217;s PF-01367338 PARP Inhibitor under a development and licensing agreement announced today worth $255 million. Pfizer’s oral and IV Poly (ADP-ribose) polymerase (PARP) inhibitor, PF-01367338 is currently  in Phase 1/2 development for solid tumors. PF-01367338 is a novel, orally active, small molecule inhibitor of PARP and will be developed by Clovis <a href='http://www.parpinhibitorscancer.com/parpinhibitornews/clovispfizerparpinhibitor.html'>[...]</a>]]></description>
		<wfw:commentRss>http://www.parpinhibitorscancer.com/parpinhibitornews/clovispfizerparpinhibitor.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ovarian Cancer and PARP Inhibitors &#8211; ONS 2010</title>
		<link>http://www.parpinhibitorscancer.com/videos/ovariancancerparpons.html</link>
		<comments>http://www.parpinhibitorscancer.com/videos/ovariancancerparpons.html#comments</comments>
		<pubDate>Sun, 22 Aug 2010 05:08:49 +0000</pubDate>
		<dc:creator>Parp Inhibitors</dc:creator>
				<category><![CDATA[Videos]]></category>
		<category><![CDATA[ovarian cancer]]></category>

		<guid isPermaLink="false">http://www.parpinhibitorscancer.com/?p=85</guid>
		<description><![CDATA[(PARP Inhibitors Video) At 2010 ONS conference in San Diego (ONS stands for &#8220;Oncology Nursing Society&#8221;), one of the hot subjects when it comes to the treatment of ovarian cancer was PARP Inhibitors. In this video, Paula J. Anastasia, RN, MN, talks about ovarian cancer recurrence and at 2:55 into the video she begins to talk about <a href='http://www.parpinhibitorscancer.com/videos/ovariancancerparpons.html'>[...]</a>]]></description>
		<wfw:commentRss>http://www.parpinhibitorscancer.com/videos/ovariancancerparpons.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Acclaimed PARP Inhibitors Researcher Dies</title>
		<link>http://www.parpinhibitorscancer.com/parpinhibitornews/parpinhibitorsresearcherdies.html</link>
		<comments>http://www.parpinhibitorscancer.com/parpinhibitornews/parpinhibitorsresearcherdies.html#comments</comments>
		<pubDate>Sun, 22 Aug 2010 04:36:20 +0000</pubDate>
		<dc:creator>Parp Inhibitors</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.parpinhibitorscancer.com/?p=81</guid>
		<description><![CDATA[(PARP Inhibitors News) Merrill J. Egorin, MD an acclaimed PARP Inhibitors and cancer researcher died on August 7, 2010 at the age of 62. Dr. Egorin&#8217;s death came five years after being diagnosed with multiple myeloma, which is a cancer of the plasma cells in bone marrow. Dr. Egorin had been a professor of medicine <a href='http://www.parpinhibitorscancer.com/parpinhibitornews/parpinhibitorsresearcherdies.html'>[...]</a>]]></description>
		<wfw:commentRss>http://www.parpinhibitorscancer.com/parpinhibitornews/parpinhibitorsresearcherdies.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>PARP Inhibitors Slow Tumor Growth in 85% of Advanced Breast Cancer Patients</title>
		<link>http://www.parpinhibitorscancer.com/research/parpinhibitorsbreastcancertumor.html</link>
		<comments>http://www.parpinhibitorscancer.com/research/parpinhibitorsbreastcancertumor.html#comments</comments>
		<pubDate>Thu, 19 Aug 2010 19:48:21 +0000</pubDate>
		<dc:creator>Parp Inhibitors</dc:creator>
				<category><![CDATA[Research]]></category>
		<category><![CDATA[breast cancer]]></category>
		<category><![CDATA[olaparib]]></category>

		<guid isPermaLink="false">http://www.parpinhibitorscancer.com/?p=78</guid>
		<description><![CDATA[Editor&#8217;s Note: The following is a press release based on a recent PARP Inhibitor study/trial. We have not edited this press release in any way. The source of the press release is Penn Medicine. It is our editorial policy to always let you know when something we publish is a press release and who the <a href='http://www.parpinhibitorscancer.com/research/parpinhibitorsbreastcancertumor.html'>[...]</a>]]></description>
		<wfw:commentRss>http://www.parpinhibitorscancer.com/research/parpinhibitorsbreastcancertumor.html/feed</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>News Story &#8211; PARP Inhibitors Show Promise</title>
		<link>http://www.parpinhibitorscancer.com/parpinhibitornews/parpinhibitorsshowpromise.html</link>
		<comments>http://www.parpinhibitorscancer.com/parpinhibitornews/parpinhibitorsshowpromise.html#comments</comments>
		<pubDate>Thu, 19 Aug 2010 01:00:58 +0000</pubDate>
		<dc:creator>Parp Inhibitors</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[breast cancer]]></category>

		<guid isPermaLink="false">http://www.parpinhibitorscancer.com/?p=71</guid>
		<description><![CDATA[(PARP Inhibitors News) Here is a news story by TV station WAVY that talks about the promise shown by PARP Inhibitors in the treatment of breast cancer. The news story follows the progress of one triple negative breast cancer patient, Sharon Price, who was able to get into a study for this new type of <a href='http://www.parpinhibitorscancer.com/parpinhibitornews/parpinhibitorsshowpromise.html'>[...]</a>]]></description>
		<wfw:commentRss>http://www.parpinhibitorscancer.com/parpinhibitornews/parpinhibitorsshowpromise.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>PARP Inhibitors and Triple Negative Breast Cancer</title>
		<link>http://www.parpinhibitorscancer.com/videos/parpinhibitorstriplenegativebreastcancer.html</link>
		<comments>http://www.parpinhibitorscancer.com/videos/parpinhibitorstriplenegativebreastcancer.html#comments</comments>
		<pubDate>Thu, 19 Aug 2010 00:36:11 +0000</pubDate>
		<dc:creator>Parp Inhibitors</dc:creator>
				<category><![CDATA[Videos]]></category>
		<category><![CDATA[breast cancer]]></category>

		<guid isPermaLink="false">http://www.parpinhibitorscancer.com/?p=68</guid>
		<description><![CDATA[(PARP Inhibitors Videos) This is a presentation that was given at the 2009 ASCO (American Society of Clinical Oncology) event. The lecture is about how chemotherapy combined with PARP Inhibitor BS-201 may be an effective new treatment option for triple negative breast cancer. The person speaking is Joyce OShaughnessy, MD from the Baylor-Charles A. Sammons <a href='http://www.parpinhibitorscancer.com/videos/parpinhibitorstriplenegativebreastcancer.html'>[...]</a>]]></description>
		<wfw:commentRss>http://www.parpinhibitorscancer.com/videos/parpinhibitorstriplenegativebreastcancer.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Breast Cancer Treatments &#8211; Parp Inhibitors</title>
		<link>http://www.parpinhibitorscancer.com/videos/breastcancertreatmentparpinhibitors.html</link>
		<comments>http://www.parpinhibitorscancer.com/videos/breastcancertreatmentparpinhibitors.html#comments</comments>
		<pubDate>Wed, 18 Aug 2010 19:27:32 +0000</pubDate>
		<dc:creator>Parp Inhibitors</dc:creator>
				<category><![CDATA[Videos]]></category>
		<category><![CDATA[breast cancer]]></category>

		<guid isPermaLink="false">http://www.parpinhibitorscancer.com/?p=64</guid>
		<description><![CDATA[(Breast Cancer and Parp Inhibitors) Below are two videos (part 1 and part 2) of a lecture given by Dr. Michael Danso of the Virginia Oncology Associates. He was asked to talk at a program called &#8220;The Many Faces of Cancer&#8221;. For his talk, he tackled new breast cancer treatments, talking about several new drugs, <a href='http://www.parpinhibitorscancer.com/videos/breastcancertreatmentparpinhibitors.html'>[...]</a>]]></description>
		<wfw:commentRss>http://www.parpinhibitorscancer.com/videos/breastcancertreatmentparpinhibitors.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>PARP Inhibitors Lecture by Dr. Devon Webster</title>
		<link>http://www.parpinhibitorscancer.com/videos/parpinhibitorslecturedevonwebster.html</link>
		<comments>http://www.parpinhibitorscancer.com/videos/parpinhibitorslecturedevonwebster.html#comments</comments>
		<pubDate>Mon, 16 Aug 2010 14:39:51 +0000</pubDate>
		<dc:creator>Parp Inhibitors</dc:creator>
				<category><![CDATA[Videos]]></category>

		<guid isPermaLink="false">http://www.parpinhibitorscancer.com/?p=59</guid>
		<description><![CDATA[Below is a great lecture video by Dr. Devon Webster on the subject of Parp Inhibitors, what they are, and how they work. She not only does a great job of explaining it in layman&#8217;s terms, but also has a sense of humor. From the video, &#8220;In cancer our goal is to kill the cells <a href='http://www.parpinhibitorscancer.com/videos/parpinhibitorslecturedevonwebster.html'>[...]</a>]]></description>
		<wfw:commentRss>http://www.parpinhibitorscancer.com/videos/parpinhibitorslecturedevonwebster.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

